BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cells » Adipose SCs » Page 2

Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using MSCs a Prophylactic Against COVID-19

June 26, 2020 By Cade Hildreth (CEO) Leave a Comment

Celltex COVID-19

June 26, 2020, HOUSTON — Celltex, a Houston, Texas-based biotechnology company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). [Read more…]

Filed Under: Adipose SCs, Cell Therapy, Coronavirus (COVID-19), MSCs, Press Releases, Stem Cell News, Stem Cells

Stem Cell Research Products | Market Size, Segments, & Trends

February 19, 2020 By Cade Hildreth (CEO) Leave a Comment

stem cells size | “Stem Cell Research Products – Opportunities, Tools, & Technologies” – Market Size, Segments, & Trends

“Stem Cell Research Products – Opportunities, Tools, & Technologies” is a global strategic report that evaluates opportunities across the entire stem cell product spectrum with an emphasis on opportunities for research product development.

This report explores market opportunities by stem cell type, including MSCs, hematopoietic stem cells, induced pluripotent stem cells, embryonic stem cells, neural stem cells, and other stem cell types.

In this article:

  • Stem Cell Categories
  • Stem Cell Research and Its Commercial Interest
  • Areas of Stem Cell Research
  • Leading Companies Offering Stem Cell Research Products

[Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells

Top 5 TED Talks About Stem Cells

October 31, 2019 By Cade Hildreth (CEO) Leave a Comment

Feature | the best ted talks | Top 5 TED Talks About Stem Cells

Check out the best TED Talks below to understand the growing importance of stem cells within regenerative medicine.

In this article:

  1. What Are TED Talks?
  2. TED Talks Topics: Stem Cells
  3. Criteria for Choosing the Top 5 TED Talks Topics About Stem Cells
  4. Top 5 Most Inspiring TED Talks About Stem Cells
    • The Skeletal Stem Cell
    • The Inconvenience of Drugs as Treatments
    • The Shift from a Whole Organ to Stem Cell Transplant
    • Stem Cells for Brain Damage
    • The In Vivo Bioreactor

[Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells

Steminent Announces FDA Approval of IND for Phase II Clinical Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia

July 18, 2018 By Cade Hildreth (CEO) Leave a Comment

Steminent FDA approval of IND

San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]

Filed Under: Adipose SCs, Press Releases Tagged With: clinical trial, Steminent

Should Stem Cells Be Regulated As Drugs?

August 17, 2017 By Cade Hildreth (CEO) 1 Comment

Should stem cells be regulated by the U.S. Food and Drug Administration (FDA) as drugs? This is a complex question and one that the FDA has continued to refine over the past several years.

FDA Regulation of Stem Cells

In the United States, cellular therapies are regulated by the FDA’s Office of Cellular, Tissue, and Gene Therapies (OCTGT) within the FDA Center for Biologics Evaluation and Research (CBER). [Read more…]

Filed Under: Adipose SCs, HSCs, Stem Cells Tagged With: regulation

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.